On April 29, 2021, Ceribell, innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced the completion of a $53 million Series C financing, which was co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group, and Red Tree Venture Capital, with additional support from existing shareholders. Wilson Sonsini Goodrich & Rosati represented Ceribell in the transaction.

Ceribell’s technology platform is designed to address the need for faster diagnosis in patients with suspicion of seizure. The company will use the financing proceeds to further expand its commercial footprint in emergency departments and intensive care units globally. In addition, Ceribell will continue to leverage the power of machine learning and easy EEG accessibility for other neurological conditions beyond seizure.

The Wilson Sonsini team that represented Ceribell in the transaction includes:

Corporate
James Huie
Daniel Cho
James Kim
Lenka Schvaigerova

Patents and Innovations
Jim Heslin
Darby Chan

Regulatory
Josh Gruenspecht
Anne Seymour
Seth Cowell

For more information, please see Ceribell's press release.